Briefing
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
MRD negativity vs positivity improved PFS (HR 0.33, 95% CI 0.29-0.37, P<.001) and OS (HR 0.45, 95% CI 0.39-0.51, P<.001), including across newly diagnosed and relapsed/refractory disease, MRD thresholds, cytogenetic risk, and method of assessment.
- Design: paper
- n: 8,098 (PFS, 44 studies); 4,297 (OS, 23 studies)
- Assay: Heterogeneous (flow and sequencing) across 44 studies